Pulse Biosciences Inc

Pulse Biosciences maintains a pristine balance sheet with $80.7 million in cash and equivalents against total liabilities of $13.9 million, resulting in a debt-to-equity ratio of 0.0. The company holds total assets of $94.5 million, with equity standing at $80.7 million. This strong liquidity position supports its ongoing operations despite the absence of commercial revenue. The current ratio is effectively infinite given the negligible liabilities relative to cash holdings, indicating no near-term solvency risk.

Profitability metrics are deeply negative, reflecting the company's pre-commercial status. Return on equity stands at -92.45%, and return on assets is -78.87%, driven by an operating income of -$76.9 million and net income of -$72.8 million. These figures are consistent with a biotechnology firm in the clinical development phase, where R&D and G&A expenses far exceed any revenue generation. The company generated only $350,000 in revenue, which is immaterial to the overall financial structure.

Revenue concentration is not applicable in the traditional sense as the company has no significant commercial segments. The $350,000 in revenue likely stems from minor licensing or collaboration activities, but no specific segment breakdown is provided. The geographic exposure is similarly undefined in the available data, though the company is listed on the Toronto Stock Exchange (PLSE.O), suggesting a primary operational base in North America.

Growth trajectory is characterized by a lack of top-line expansion, with revenue remaining negligible. The historical periods data is not provided, but the current financial snapshot indicates a static revenue base. The company's growth potential is tied to the clinical success of its pipeline rather than current sales trends. The operating cash flow of -$54.1 million highlights the cash burn rate associated with clinical trials and corporate overhead.

Risk assessment indicates low liquidity risk and low dilution risk. The key flags section notes no immediate filing-based liquidity or dilution flags. The primary risk is clinical execution risk, which is inherent to the biotechnology sector. The company's ability to raise additional capital if needed is supported by its strong cash position, but future dilution may occur if equity financing is required to fund later-stage trials.

Recent events include analyst coverage with a mean price target of $30.67 and a median target of $30.00. The mean recommendation is 1.67, indicating a strong buy consensus among the three analysts covering the stock. There are no recent filing or news observations provided, but the analyst sentiment suggests confidence in the company's clinical prospects.

The company maintains zero long-term debt, resulting in a debt-to-equity ratio of 0.0, which significantly reduces financial leverage risk.

Analysts assign a mean price target of $30.67, implying a modest 1.2% upside from the current market price of $30.30.

Operating losses improved by 26.9% year-over-year, decreasing from $76.9 million to $56.3 million, indicating better cost management.

The firm holds a strong liquidity position with a current ratio of 10.53, suggesting ample short-term assets to cover liabilities.

Risk flags for both liquidity and dilution are rated as low, suggesting minimal immediate threats to capital structure stability.

The company recorded a net loss of $53.6 million, resulting in a net margin of -99.3%, which ranks in the bottom quartile.

Free cash flow burned $52.5 million, reflecting significant ongoing cash consumption without corresponding revenue generation to offset costs.

Operating margin of -103.9% is in the bottom quartile, indicating severe inefficiency in converting revenue into operating profit.

Revenue $401.0k; Operating income −6,1% YoY.

• ▍Revenue $401.0k
• ▍Operating income −6,1% YoY
• ▍Net income −10,6% YoY
• ▍Free cash flow −10,9% YoY
• ▍Net margin -4633.7%

Revenue $264.0k; Operating income +9,9% YoY.

• ▍Revenue $264.0k
• ▍Operating income +9,9% YoY
• ▍Net income +10,1% YoY
• ▍Free cash flow +9,8% YoY
• ▍Net margin -6603.4%

Revenue $86.0k; Operating income −49,1% YoY.

• ▍Revenue $86.0k
• ▍Operating income −49,1% YoY
• ▍Net income −52,9% YoY
• ▍Free cash flow −54,4% YoY
• ▍Net margin -22540.7%

Revenue $0.00; Operating income −72,9% YoY.

• ▍Revenue $0.00
• ▍Operating income −72,9% YoY
• ▍Net income −68,4% YoY
• ▍Free cash flow −71,1% YoY

Revenue $350.0k; Operating income −36,8% YoY.

• ▍Revenue $350.0k
• ▍Operating income −36,8% YoY
• ▍Net income −35,8% YoY
• ▍Free cash flow −37,1% YoY
• ▍Net margin -20794.6%

Revenue $0.00, −100,0% YoY; Operating income +24,9% YoY.

• ▍Revenue $0.00, −100,0% YoY
• ▍Operating income +24,9% YoY
• ▍Net income +27,9% YoY
• ▍Free cash flow +28,5% YoY

Revenue $700.0k, −50,6% YoY; Operating income +7,9% YoY.

• ▍Revenue $700.0k, −50,6% YoY
• ▍Operating income +7,9% YoY
• ▍Net income +8,1% YoY
• ▍Free cash flow +8,6% YoY
• ▍Net margin -8357.9%

Revenue $1.4M; Operating income -$63.0M.

• ▍Revenue $1.4M
• ▍Operating income -$63.0M
• ▍Net margin -4489.4%